await rivipansel top-line data
report earn gave updat lead asset rivipansel
partner w/ uproleselan next catalyst rivipansel top-line
data management review broad piii dev program uproleselan
addit pivot studi sever consortia trial initi
could help expand upro potenti use r/r aml frontlin aml
partner confid top-line rivipansel data recal timelin
shift w/ studi enrol call management note
greater challeng acut set enrol given sickl cell pt crisi present
hospit errat time latest timelin base pt accrual rate past
mo management express high degre confid complet enrol
earli recal time readiness-for-discharg agre upon spa
w/ fda management emphas rivipansel would on-demand product sickl
cell crisi approv contrast tx develop prophylaxi
piii follow open-label extens studi could support usag sub-
acut set addit in-hospit
consortia trial could suppli data uproleselan label expans aml
management expect initi piii registr studi top-line data expect
given os addit management highlight nci-fund trial initi
evalu upro add-on therapi older adult age w/ newli
diagnos aml fit chemo studi contain plan interim analysi ef
first pt enrol hovon group conduct anoth trial eu
enrol older pt unfit intens chemo also expect initi management
note co support provid data monitor ensur result consortia
trial could use regulatori purpos approach success employ
novarti help secur approv midostaurin aml
pipelin updat top-line data pi open-label studi upro add-on therapi
velcade/kyproli multipl myeloma expect studi evalu
reduct m-protein level signal activ dual
inhibitor current pi studi management plan announc indic dev
financi report dilut ep vs estimate con
co cash end
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
approv rivipansel sickl cell vaso-occlus crisi
voc us eu
rivipansel peak revenu risk-adj us
risk-adj eu
approv uproleselan r/r aml frontlin aml
us
uproleselan peak revenu risk-adj us
rivipansel voc de-risk posit clinic data
hospit includ outpati er/clin set
uproleselan aml de-risk posit clinic
uproleselan expand label frontlin aml and/or
early-stag pipelin asset repres
rivipansel success develop voc
uproleselan success develop r/r frontlin
early-stag pipelin asset
model us approv rivipansel eu approv
risk discount
thalassemia voc opportun
model royalti us eu
sale rivipansel
model us approv uproleselan r/r aml frontlin
aml risk discount
includ r/r elderli frontlin fit elderli frontlin unfit
non-elderli frontlin patient overal aml opportun
initi piii registr trial uproleselan r/r aml
initi nci combo trial uproleselan
chemo elderli frontlin fit aml
initi eu hovon combo trial uproleselan
hma decitabin elderli frontlin unfit aml
top-line data piii trial rivipansel voc
top-line data pi poc trial uproleselan multipl
top-line data piii registr trial uproleselan
page
pleas see import disclosur inform page report
pt base dcf valuat model assum wacc termin
growth rate outstand share million driven potenti sale
rivipansel estim peak us rivipansel sale unadjust
risk-adjust peak us unadjust
risk-adjust estim us approv launch rivipansel
late believ rivipansel approv eu
clinic failur compani
biotechnolog pharmaceut
develop treatment futur clinic failur lead delay approv
possibl discontinu program
regulatori failur fda could determin new drug applic inadequ
rivipansel could delay approv delay approv timelin
could impact earn estim price target and/or rate
commerci failur current project million risk-adjust peak
sale rivipansel estim may reli success
company/partn receiv drug reimburs private/publ payor
financ risk expect compani adequ cash may need
addit financ beyond fund potenti launch rivipansel
fund addit indic
page
pleas see import disclosur inform page report
